GlobalData Healthcare

In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD), marking the world’s first clustered regularly interspaced short palindromic repeats (CRISPR)-based approval. Last month, the National Institute for […]

The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the 149 approvals in 2023. However, there was an abundance of innovation and firsts among 2024’s approvals. Numerous small pharma companies secured

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence in its cystic fibrosis (CF) pipeline, particularly its lead candidates, SION-719 and SION-451, which work by stabilising the nucleotide‐binding domain

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar. However, these drugs also act on the brain’s reward system, an area deeply involved in addiction.

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of Health (NIH), signalling headwinds in securing NIH grant funding for biopharmaceutical research and development (R7D). NIH Small Business Innovation

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) – the US, France, Germany, Italy, Spain, the UK, and Japan – is projected to experience significant growth, with sales increasing from $2.3bn in 2023 to $5.2bn by

Drugs targeting the glucagon-like peptide-1 receptor (GLP-1R) demonstrated remarkable success in 2023, with approved products generating sales of $37.2 billion. Currently, there are 323 active GLP-1Rs in the pipeline, with several estimated to deliver significant returns upon launch. While mega-cap

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications. According to leading data and analytics company GlobalData,

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin

Severe asthma is traditionally classified into either high or low T-helper cell type 2 (T2) subtypes. T2-high asthma, which is characterised by allergic inflammation and elevated eosinophil levels, has seen significant advances in treatment and disease management with the advent